secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-038729
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm FY2022 net loss $24.3M; cash drops to $3M; FDA ADCOM for NurOwn BLA
------------------------------------------------------------------------------

- Net loss of $24.3M ($0.66 per share) vs $24.5M ($0.68) in 2021; no revenue.
- Cash and short-term deposits fell to $3M from $22M at year-end 2021.
- R&D expenses $14M, G&A $10.9M; combined $24.9M operating spend.
- FDA will hold Advisory Committee meeting to review NurOwn BLA for ALS; File over Protest used.
- Dr. Stacy Lindborg promoted to Co-CEO in January 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923038729/0001104659-23-038729-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923038729/tm2310964d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-038729

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer